Treating Triple-Negative Breast Cancer

Slideshow

This slide deck covers the treatment of triple-negative breast cancer, a heterogeneous disease made up of numerous subtypes, and includes clinical variables that can help with prognosis and guide in treatment choice.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Related Content
No treatment-related discontinuations have been observed related to Bria-IMT treatment for hormone receptor–positive breast cancer.

Bria-IMT Enhances Survival vs Sacituzumab Govitecan in HR+ Breast Cancer

Roman Fabbricatore
August 15th 2025
Article
Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber on PARP Inhibitors for Triple-Negative Breast Cancer

Judy Garber, MD, MPH
August 15th 2025
Podcast
Roshni Rao, MD, FACS, discussed the use of neoadjuvant chemoimmunotherapy and its complications in the treatment of patients with triple-negative breast cancer.

Questions Remain Around Neoadjuvant Chemoimmunotherapy in TNBC

Kristie L. Kahl
August 15th 2025
Article
Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Atezolizumab in Triple-Negative Breast Cancer Improved Survival Among Responders

Peter Schmid, MD
August 15th 2025
Podcast
The phase 3 IMpassion030 trial did not find a survival benefit when atezolizumab was added to chemotherapy after surgery for patients with triple-negative breast cancer.

Adjuvant Atezolizumab Plus Chemo Does Not Add Survival Benefit in TNBC

Ariana Pelosci
August 15th 2025
Article
The final overall survival analysis of trilaciclib plus chemotherapy in patients with metastatic triple-negative breast cancer as part of the PRESERVE 2 trial will take place in the third quarter of 2024.

Phase 3 Trial of Trilaciclib in Triple-Negative Breast Cancer Will Continue

Russ Conroy
August 15th 2025
Article